A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer is a research paper published in Journal of Gastrointestinal Cancer (2024). On theSindex it has a DataRank of 0.227. It has been cited 3 times, with 3 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0.0190
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 3 citers.
National Institutes of Health
Grant: 1UM1-CA186704-01
NCI NIH HHS
Grant: UM1 CA186717
NCI NIH HHS
Grant: P30 CA014089
NCI NIH HHS
Grant: UM1 CA186704
National Institutes of Health
Grant: 2UM1CA186717-06
Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
National Institutes of Health
Grant: 5UM1CA186704-05
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
National Institutes of Health
Grant: 3P30CA014089-17S1
USC COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
FWCI
0.71
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals